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Abstract 
Background: Long term infection with HIV‑1, even in the context of therapy, leads to chronic health problems 
including an array of neurocognitive dysfunctions. The viral Tat protein has previously been implicated in neuropatho‑
genesis through its effect on astrocytes. Tat has also been shown to inhibit the biogenesis of miRNAs by inhibiting 
the activity of the cellular Dicer protein in an RNA dependent fashion. Whether there is a mechanistic connection 
between the ability of HIV‑1 Tat to alter miRNAs and its observed effects on cells of the central nervous system has not 
been well examined.
Results: Here, we examined the ability of HIV‑1 Tat to bind to and inhibit the production of over 300 cellular miR‑
NAs. We found that the Tat protein only binds to and inhibits a fraction of the total cellular miRNAs. By mapping the 
downstream targets of these miRNAs we have determined a possible role for Tat alterations of miRNAs in the develop‑
ment of neuropathogenesis. Specifically, this work points to suppression of miRNAs function as the mechanism for Tat 
suppression of β‑catenin activity.
Conclusions: The discovery that HIV‑1 Tat inhibits only a fraction of miRNAs opens new areas of research regarding 
changes in cellular pathways through suppression of RNA interference. Our initial analysis strongly suggests that these 
pathways may contribute to HIV‑1 disruption of the central nervous system.
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Background
Acquired immunodeficiency syndrome (AIDS) is a com-
plex and multifaceted disease that arises from the infec-
tion of CD4+ T-cells by the human immunodeficiency 
virus (HIV-1). Advances in HIV research have provided 
us with anti-retroviral drugs that target various viral 
enzymes like reverse transcriptase, protease and inte-
grase. Although these anti-retroviral drugs control rep-
lication of the virus no permanent cure has yet been 
discovered. Viral replication is positively regulated by the 
interaction between the viral Tat protein and an RNA ele-
ment called transactivation response (TAR) element. The 
Tat protein binds to the nascent TAR RNA and recruits 
positive elongation complex (pTEFb) that enhances the 
rate and efficiency of HIV-1 transcription. HIV-1 invades 
the central nervous system (CNS) within a few weeks of 
infection and sets the stage for potentially severe inflam-
matory events. Anti-retroviral drugs poorly penetrate 
the blood–brain barrier of the CNS allowing low level 
ongoing replication in the CNS that leads to moderate to 
severe HIV-associated dementia [1, 2]. The overall spec-
trum of viral neuropathogenesis is collectively referred 
to as HIV-associated neurocognitive disorders (HAND). 
HIV-1 does not infect neurons, implying that HAND 
must be mediated in an indirect fashion. The HIV-1 Tat 
protein has been shown to cross the cell membrane and 
have an effect on bystander cells [3–6]. Furthermore, 
Tat has been implicated in neurological diseases [7–11] 
and specific mutations within Tat correlate with clade-
specific differences in the prevalence of HAND [11–13]. 
Specifically, Tat exposure has been shown to contribute 
to dysfunction of the dopaminergic system, influence 
dopaminergic uptake kinetics and alter the expression of 
opiate neuropeptides and receptors [14–16]. Substantial 
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evidence exists that these effects are exacerbated by 
exposure to opiate drugs [7, 17–19].
Studies have examined the interplay between Tat, 
infection of astrocytes and opiate drugs that affect 
brain function. However, none of the studies have 
examined the role of microRNA (miRNA) in the Tat-
HAND axis. RNA interference (RNAi) is a regulatory 
mechanism found in plants, nematodes, protozoan, 
Drosophila, and mammalian cells [20–22]. Double 
stranded RNA is recognized by the RNAi machinery 
and is processed into small, 21 nucleotide small-inter-
fering RNA (siRNA) which are capable of suppressing 
gene expression. Endogenously expressed RNA can be 
involved in RNAi through a pathway involving Drosha 
mediated cleavage of RNA stem-loops in the nucleus, 
followed by exportation to the cytoplasm by Expor-
tin-5, and finally cleavage of this pre-miRNA by Dicer 
to generate a small RNA duplex, called miRNA [23–
28]. This miRNA guides the RNA-induced silencing 
complex (RISC) to a complementary, but not perfectly 
matching, region in the target mRNA. This association 
inhibits protein translation with minimal effect on the 
target mRNA [21, 29, 30].
Preliminary studies have shown that the viral Tat pro-
tein inhibits miRNA function [31], not by blocking RISC 
complex directly, but by binding to the Dicer protein that 
plays a role in the production of miRNA [32]. A follow 
up to these studies revealed that alteration of miRNA by 
Tat–Dicer complex occurs in an RNA-dependent manner 
[33]. As Tat inhibition of miRNA biogenesis is not due to 
direct suppression of Dicer, but through the binding of 
RNA, this opens the intriguing possibility that Tat may 
be selectively inhibiting specific miRNAs. In this paper, 
we examine the association of Tat with specific miRNAs 
and determine what cellular pathways are affected by Tat 
driven changes in miRNA expression.
Our findings suggest that HIV-1 Tat protein inhib-
its only a subset of miRNAs and leads to the observed 
phenotypic changes in astrocytes within the CNS in 
HIV-infected patients. Our identification of specific 
miRNAs that are tightly bound to Tat protein suggests 
downstream effects in Wnt/β-catenin signaling pathway. 
Wnt/β-catenin signaling is a large and complex pathway 
known to play a role in numerous cellular activities like 
cell differentiation, survival and proliferation. Knock-
down studies have shown that β-catenin plays a role in 
repression of basal HIV-LTR transcription [34, 35]. As 
such, by repressing the rate and efficiency of HIV-1 tran-
scription, β-catenin serves as a cellular restriction factor 
in the CNS. This work identifies a mechanism by which 
Tat protein represses β-catenin activity, thereby pro-
moting neuroinflammatory activities in HIV-infected 
patients.
Results and discussion
HIV‑1 Tat binds to a specific subset of cellular microRNAs
Previous studies have shown that Tat interacts with 
Dicer only in the presence of RNA [33]. Here, we exam-
ined which miRNAs are capable of binding to Tat in vivo. 
In order to identify which miRNAs interact with Tat, 
we transfected flag-tagged wild-type Tat plasmid into 
HEK293T mammalian cells and immunoprecipitated 
using anti-flag antibody, isolated RNA and measured the 
expression of five miRNAs: let7a, miR16, miR17, miR138 
and miR326 (Fig. 1). miR16, miR17 and miR138 showed 
Tat interaction while let7a and miR326 did not bind to 
Tat protein. When Tat was mutated at position K51A, a 
residue previously shown to be critical to Tat inhibition 
of Dicer activity, the interaction between Tat and miR17 
and miR138 was lost [33]. Interestingly, the IP of Tat 
K41A, which is incapable of transactivating the HIV-1 
LTR but still has ability to inhibit Dicer function, showed 
similar miRNA binding as wild-type Tat.
In order to expand our preliminary findings, we per-
formed immunoprecipitation of flag-tagged wild-type 
Tat from 293T cells and measured association with 380 
human miRNAs (Fig.  2). After making a present-absent 
call, the data was normalized on a per-array basis and the 
enrichment of miRNAs by Tat was graphed as the ratio 
of Tat-associated to the whole cell level of each miRNA. 
Out of 380 miRNAs measured, 68 miRNAs were found to 
have at least some interaction with Tat protein (Fig. 2a). 
Fig. 1 Tat association with cellular miRNA. HEK 293T cells were 
transfected with Flag Tat‑WT, K51A or K41A. Forty‑eight hours post‑
transfection Tat complexes were isolated by anti‑Flag IP and RNA was 
extracted from these complexes or whole cells. RT‑qPCR was used to 
determine if target miRNA associated with Tat complex
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Of these 68 miRNAs bound to Tat, 18 miRNAs showed 
consistent enrichment of greater than twofold and were 
considered tight Tat binders (asterisk in Fig. 2a). On fur-
ther analysis on these 18 miRNAs, ten miRNAs were 
found to be down regulated at the whole cell level when 
Tat protein was expressed (Table 1). To rule out the pos-
sibility that overall expression levels of a given miRNA 
were influencing the amount of miRNA measured in 
the Tat IP we graphed the whole cell levels of the 68 Tat 
associated miRNAs (Fig.  2b). No correlation was found 
between total expression levels and Tat binding. These 
results showed that Tat binds and inhibits the production 
of only a subset of possible miRNAs.
HIV‑1 Tat alters miRNAs with potential roles in the CNS
Each individual miRNA is capable of potentially target-
ing dozens of mRNA transcripts and, depending on 
context and the number of targeting miRNA, have wide 
range of effect on protein expression. As such, we felt it 
was best to approach the issue of downstream effects in 
a holistic fashion that would look for the net outcome of 
changes in all of the 18 tight Tat binders. We employed 
ingenuity pathway analysis software (IPA) to predict the 
potential protein targets of the 18 tight Tat binders and 
then determine what pathways these proteins belong to. 
IPA analysis showed a strong probability of Tat altera-
tion of miRNAs being involved in several processes 
Fig. 2 Identification of miRNAs tightly bound by Tat complex. HEK 293T cells were transfected with Flag Tat plasmid and Tat complexes were 
isolated 48 h post‑transfection using anti‑Flag IP. a RNA from Tat complexes and whole cells was used as input into a polyA mediated RT‑qPCR array 
capable of detecting over 300 human miRNAs. Shown is the fold enrichment in the Tat complex of the 68 miRNAs found to bind to Tat. The miRNAs 
indicated by asterisk show a twofold enrichment in the Tat complex as compared to the whole cell in all replicates. b Corresponding levels of miRNA 
in the whole cell RNA fraction
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related to HIV-1 pathogenesis: Wnt/β-catenin signal-
ing cascade (p  =  9.06  ×  10−9, Fig.  3), axonal guidance 
(p =  5.92E−18, Fig.  4), glucocorticoid receptor signaling 
(p = 1.23 × 10−11, not shown) and nerve growth factor 
signaling (p  =  1.3  ×  10−14, not shown) [36–40]. Previ-
ous studies have shown that alterations of β-catenin in 
HIV-1 infected CNS is likely a necessary step for infec-
tion of astrocytes and eventual neuropathogenesis [38]. 
From our analysis, we show that Tat has a role in the 
neuropathogenesis of CNS by its suppression of specific 
miRNAs that are involved in Wnt/β-catenin signaling or 
axonal guidance pathway.
HIV‑1 Tat downregulates β‑catenin activity in a miRNA 
dependent manner
Our IPA analysis suggested an effect on Wnt/β-catenin 
signaling when wild-type Tat protein is expressed. To 
confirm an effect on beta-catenin and the involvement of 
miRNAs, we performed a β-catenin responsive reporter 
gene assay to look at the β-catenin activity in an astro-
cyte cell line, U-87MG (Fig.  5). Previous studies have 
shown that lithium chloride (LiCl) enhances the activity 
of β-catenin in cells. Therefore, we performed luciferase 
assay with wild-type Tat in presence of LiCl. Transfection 
of U-87MG with increasing amounts of wild-type Tat 
showed a dose dependent decrease in β-catenin activity 
when compared to just LiCl treatment (Fig.  5a). This is 
consistent with earlier reports that Tat is capable of inac-
tivating β-catenin. Interestingly, when transfecting Tat 
K41A a significant decrease in β-catenin activity was not 
observed (Fig.  5b). A previous study has already identi-
fied lysine 41 as an important residue in β-catenin modu-
lation [34]. The Tat K51A mutant, which is incapable of 
binding to miRNA, induces a slight, but statistically sig-
nificant suppression of β-catenin activity. However the 
suppression of β-catenin activity by Tat K51A is signifi-
cantly weaker than wild-type Tat. This new data confirms 
a role for lysine 51 and its ability to modulate miRNA 
interaction and suppression in the ability of Tat to sup-
press β-catenin activity.
To confirm that the identified miRNAs could mediate 
the downregulation of the β-catenin signaling pathway 
we used miRNA inhibitors (antagomirs) to block the 
effect of miRNAs. Antagomirs complementary to miR-
NAs predicted to target β-catenin were transfected into 
U-87MG along with a β-catenin responsive reporter gene 
(Fig.  6a). Inhibition of miR-135 and miR-181 induced a 
statistically significant reduction of β-catenin activity in 
U-87MG astrocytes. Blocking the effect of miR-539 and 
miR-129 had no effect. Interestingly, inhibition of let-7 
induced a dose dependent increase in β-catenin activity. 
The reduction of β-catenin activity mediated by miR-181 
was confirmed also in HeLa cells (Fig. 6b).
HIV‑1 Tat alters the morphology of U‑87MG astrocyte cells
When U-87MG was treated with LiCl we observed a 
striking change in morphology that correlated with the 
activity of β-catenin. Specifically, the cells appeared more 
spindle-like with significant branching when compared 
to the normal morphology of U-87MG (Additional file 1: 
Table 1 miRNAs associated with Tat protein
miRNA Fold enrichment Down  
regulated?






let‑7i 7.6E+00 Yes X X X X
miR‑129‑3p 2.5E+00 Yes X X X X
miR‑132 1.7E+01 X X X
miR‑135a 2.0E+02 Yes X X X X
miR‑135b 2.6E+02 Yes X X X X
miR‑140‑5p 7.6E+01 X X X
miR‑181a 1.5E+02 Yes X X X X
miR‑181b 1.4E+02 Yes X X X X
miR‑181c 1.6E+02 X X X X
miR‑216b 1.3E+01 X X X X
miR‑376c 2.2E+01 X X X X
miR‑499‑3p 9.6E+01 Yes X X X
miR‑512‑3p 5.1E+01 X X
miR‑513c 1.2E+02 X X X
miR‑519d 7.2E+00 X X X X
miR‑523 1.5E+02 Yes
miR‑524‑3p 1.7E+02 Yes X
miR‑539 6.1E+00 Yes X X X X
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Figure S1). This morphology appears similar to proto-
plasmic astrocytes seen in brain tissue. However, when 
wild-type Tat was transfected into U-87MG prior to the 
introduction of LiCl, the cells seemed to lose their spin-
dle-like structure and appeared smaller, similar to the 
morphological changes observed in the brains of HIV-1 
infected patients suffering from HAND.
Conclusions
It has been previously reported that HIV-1 Tat protein 
binds and inhibits Dicer in a RNA-dependent manner. 
In the current study, we show that Tat protein binds and 
inhibits the production of only certain cellular miRNAs. 
We identified 68 miRNAs that have some interaction 
with Tat protein. Out of these 68 miRNAs, we found that 
18 showed more than twofold enrichment with Tat and 
were categorized as tight Tat binders. When the potential 
targets of these 18 tight Tat binders were analyzed, it was 
found that these miRNAs were likely involved in either 
axonal guidance, glioma signaling, glucocorticoid syn-
thesis or canonical Wnt/β-catenin signaling in the CNS. 
On further investigating the role of HIV-1 Tat in Wnt/β-
catenin signaling via miRNA inhibition, it was found 
that Tat inhibits the activity of β-catenin in a miRNA 
Fig. 3 Targeting of the Wnt/β‑catenin signaling pathway by Tat altered miRNAs. Ingenuity pathway analysis software was used to predict the 
downstream targets of the 18 tight Tat binders and to visualize the Wnt/β‑catenin pathway. Proteins with symbols filled in gray are targets of Tat 
bound miRNAs. miRNAs confirmed to be down‑regulated at the whole cell level are shown on the right. The dashed lines depict the targets of these 
eight miRNAs
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dependent manner. From previous studies, it has been 
noted that repression of β-catenin has a role to play in the 
neuropathogenesis of HIV. Here, we report that HIV-1 
Tat indirectly inhibits the β-catenin activity via miRNA 
inhibition and this alteration of miRNA likely has a sig-
nificant role to play in the neuropathogenesis of HAND 
in HIV-1 infected patients.
Our findings highlight the importance of the lysine 
residues at both position 41 and 51 of Tat. The K41A 
mutant and K51A mutant have previously been shown 
to have different effects: loss of transactivation ability 
and loss of Dicer inhibition respectively. That both motifs 
are required for efficient suppression of β-catenin activ-
ity is of interest. Additional work must be performed to 
expand our understanding of the mechanisms by which 
these motifs inhibit β-catenin. Additionally, other path-
ways involved in the pathogenesis of HAND that might 
be affected by alterations in miRNA must be evalu-
ated. Previous studies have shown that opiate drugs like 
morphine exacerbate the neuropathogenesis in the CNS. 
This opens the intriguing possibility that opiates and Tat 
alter similar miRNA subsets. Continued examinations 
of the alterations of miRNAs, as well as the downstream 
effects of such alterations, could open up pathways to 




HEK 293T and HeLa were cultured in Dulbecco’s Modi-
fied Eagle Medium and U-87MG were cultured in Eagles 
Minimal Essential Media, supplemented with 10 % Fetal 
bovine serum, 4.5 g/l of l-glutamine and penicillin/strep-
tomycin. Cells were grown in 75  cm2 polystyrene flask 
under standard conditions at 37  °C with 5 % CO2. WT-
Tat, K41A-Tat, K51A-Tat and CMV-GFP expression vec-
tors were transfected into HEK 293T cells in 9.60  cm2 
wells with TransFectin Lipid Reagent (Bio-Rad, Hercules, 
Fig. 4 Targeting of the axonal guidance signaling by Tat altered miRNA. Ingenuity pathway analysis software was used to predict the downstream 
targets of the 18 tight Tat binders and to visualize the Wnt/β‑catenin pathway. The targets of the miRNAs bound by Tat are filled in with gray. miR‑
NAs confirmed to be down‑regulated at the whole cell level are shown on the left. The dashed lines indicate targets of these eight miRNAs
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CA, USA). Cells were harvested after 48 h post-transfec-
tion, centrifuged for 2 min at 1500 rpm, washed 2 times 
with ice-cold phosphate buffered saline (PBS), lysed with 
50  µl RIPA buffer [(150  mM NaCl, 1  % NP-40, 0.5  % 
sodium deoxycholate, 0.1 % SDS, 50 mM Tris (pH 8.0)] 
and put on ice for 30  min. Cell suspensions were cen-
trifuged for 5 min at 14,000 rpm and supernatants were 
stored at 20  °C for further analysis. For the luciferase 
assay, U-87MG and HeLa were cultured in 96-well plate 
and transfected with TransFectin Lipid Reagent (Bio-Rad, 
Hercules, CA, USA). miRNA inhibitors were obtained 
from GE Dharmacon (Miridian miRNA inhibitors).
Co‑immunoprecipitation
Co-IP was performed using the Pierce classic IP kit. In 
brief, 1 mg cell lysate from each transfected sample was 
prepared with IP lysis buffer. Cell lysate (1 mg) was added 
to Pierce Spin Column, containing 80  µl of the Control 
Agarose Resin Slurry and incubated at 4 °C for 1 h on a 
rocker. The binding of antibody to protein was facili-
tated by addition of 2  µg of monoclonal anti-Flag anti-
body (ThermoFisher Scientific, monoclonal clone L5) to 
tubes containing pre-cleared cell lysate. The tubes were 
incubated at 4  °C overnight with constant shaking. The 
prepared Pierce Protein A/G Agarose beads were added 
to the antibody-protein solution and incubated for 1  h 
at 4  °C with constant shaking. The antibody-protein-
agarose bead solution was centrifuged in a 1.5 ml collec-
tion tube (ThermoFisher Scientific, Rockford, IL, USA) 
at 1000g for 1  min. The supernatant was discarded and 
the pellet was placed in a new collection tube. The pellet 
was washed three times with Pierce IP Lysis/Wash Buffer 
and finally with 100 µl of 1× conditioning buffer (diluted 
from 100× ThermoFisher Scientific Conditioning Buffer). 
The immune complex (antibody-protein-agarose bead) 
was eluted by addition of 500 µl of Trizol Reagent (Inv-
itrogen, Carlsbad, CA, USA) to the Pierce spin column.
RNA extraction and RT‑PCR
The homogenized immune complex in Trizol obtained 
from Co-IP was incubated for 5 min at room temperature 
and centrifuged at 1000g for 1 min to obtain the dissoci-
ated nucleoprotein complex in a new collection tube. The 
elution was followed by addition of 100 µl of chloroform 
for phase separation as per the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA, USA). In order to precipi-
tate RNA from aqueous phase, 250  µl of 100  % isopro-
panol was used. The pellet was washed with 500  µl of 
75 % ethanol and centrifuged at 7500g for 5 min at 4 °C. 
Total RNA was resuspended in 40 µl of RNase-free water 
(5 Prime, Hilden, Germany) and incubated at 60  °C for 
15 min. The total yield of isolated RNA was determined 
using NanoDrop (ThermoFisher Scientifc, Rockford, IL, 
USA). RNA extraction was repeated in a similar manner 
with 100 µg of whole cell lysates 89.5 ng of total RNA was 
used to measure miRNA using the QuantiMiR RT Kit 
(System Biosciences).
Real‑time qPCR and miRNA profiling
Real-time PCR was carried out using System Biosciences 
miRNome miRNA Profilers QuantiMir Kit (System Bio-
sciences, Mountain View, CA, USA) following the com-
pany protocol. Analysis was limited to the first plate in 
the microRNome array, which contains the most com-
monly studied miRNAs. Previous studies have shown 
that this method allows the detection of both pre-miRNA 
and mature miRNA [41, 42].
Luciferase activity
β-Catenin activity was measured by transfection of cells 
with TCF-LEF Reporter system (SABiosciences). To 
activated β-catenin, cells were treated with either 10 or 
Fig. 5 HIV‑1 Tat inhibits β‑catenin activity in U‑87MG cells. a U‑87MG 
were transfected with a β‑catenin responsive luciferase vector and 
increasing concentrations of Tat expression vectors at the indicated 
amounts. Twenty‑four hours later the cells were treated with LiCl to 
induce activation of β‑catenin. Twenty‑four hours post LiCl treatment 
luciferase activity was measured and displayed as a percentage 
of maximal activity. b Indicated Tat mutants were transfected into 
U‑87MG alongside reporter and measured as above. *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001
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50 mM LiCl. β-catenin responsive luciferase levels were 
measured using the Dual-Glo® Luciferase Assay System 
(Promega). Firefly luciferase responsive to beta-catenin 
was normalized to renilla luciferase internal control.
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